Stocks · News reference
HCW Biologics Signs Agreement With Akron Biotech To Commercialize HCW11-006 To Use As Reagent For New Method Of Human CAR-T Cells Production To Treat Cancer
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HCW Biologics Files Prospectus For Resale Of Up To 1,807,228 Shares Underlying Armistice Capital Warrants
https://www.sec.gov/Archives/edgar/data/1828673/000149315226045532/forms-1.htm
HCW Biologics shares are trading higher after the company announced pricing of $1.5 million private placement.
8-K filing — HCW Biologics Inc. (HCWB)
Filed: 2026-09-24 AccNo: 0001493152-26-044078 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits